Jessica Robinson-Papp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jessica Robinson-Papp has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
David M. Simpson
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA
10 shared publicationsMary Catherine George
Department of Neurology, Icahn School of Medicine at Mount Sinai , New York, New York
10 shared publicationsSusan Morgello
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
10 shared publicationsBridget R. Mueller
Icahn School of Medicine at Mount Sinai, Department of Neurology
8 shared publicationsAlexandra Nmashie
Department of Neurology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, USA
7 shared publicationsGabriela Cedillo
Department of Neurology, Icahn School of Medicine at Mount Sinai , New York, New York
5 shared publications
Latest Publications
- Open Access
Gut Microbiome-Mediated Neuroprotective Effect of the Mediterranean Diet: A Narrative Review of Cognitive Aging, Alzheimer’s Disease, and Parkinson’s Disease
Background: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are major neurodegenerative disorders for which disease-modifying therapies are limited. Increasingly, evidence suggests that diet influences neurodegenerative risk through interactions among the gut microbiome, immune system, and brain. The Mediterranean diet (MD) is associated with improved cognitive health, but the mechanisms underlying its potential neuroprotective effects remain incompletely understood. Objective: In this narrative review, evidence on microbiome-mediated mechanisms linking MD adherence to neuroprotection was synthesized, and how Mediterranean dietary components influence microbial ecology, metabolites, immune regulation, and neuroinflammation relevant to cognitive aging, AD, and PD was evaluated. Methods: Evidence from experimental, observational, and clinical studies was reviewed, focusing on microbial metabolites, intestinal barrier integrity, immune regulation, and inflammatory pathways. Discussion: Mediterranean dietary components, including fiber, polyphenols, whole grains, legumes, nuts, extra-virgin olive oil, and omega-3 fatty acids, may promote beneficial microbial communities and metabolite production. Short-chain fatty acids, secondary bile acids, indole derivatives, and phenolic metabolites may strengthen the intestinal and blood–brain barriers, regulate immune responses, and suppress neuroinflammation. Conversely, dysbiosis may increase intestinal permeability, lipopolysaccharide translocation, systemic inflammation, and microglial activation. However, evidence remains heterogeneous and largely observational or experimental. Conclusions: The MD may promote neuroprotection through interconnected diet–microbiome–immune pathways. Longitudinal and intervention studies integrating microbiome, metabolomic, inflammatory, neuroimaging, and cognitive measures are needed to establish causality and advance precision nutrition strategies to prevent neurodegenerative disease.
Open AccessGut Microbiome-Mediated Neuroprotective Effect of the Mediterranean Diet: A Narrative Review of Cognitive Aging, Alzheimer’s Disease, and Parkinson’s Disease
Background: Alzheimer’s disease (AD) and Parkinson’s disease (PD) are major neurodegenerative disorders for which disease-modifying therapies are limited. Increasingly, evidence suggests that diet influences neurodegenerative risk through interactions among the gut microbiome, immune system, and brain. The Mediterranean diet (MD) is associated with improved cognitive health, but the mechanisms underlying its potential neuroprotective effects remain incompletely understood. Objective: In this narrative review, evidence on microbiome-mediated mechanisms linking MD adherence to neuroprotection was synthesized, and how Mediterranean dietary components influence microbial ecology, metabolites, immune regulation, and neuroinflammation relevant to cognitive aging, AD, and PD was evaluated. Methods: Evidence from experimental, observational, and clinical studies was reviewed, focusing on microbial metabolites, intestinal barrier integrity, immune regulation, and inflammatory pathways. Discussion: Mediterranean dietary components, including fiber, polyphenols, whole grains, legumes, nuts, extra-virgin olive oil, and omega-3 fatty acids, may promote beneficial microbial communities and metabolite production. Short-chain fatty acids, secondary bile acids, indole derivatives, and phenolic metabolites may strengthen the intestinal and blood–brain barriers, regulate immune responses, and suppress neuroinflammation. Conversely, dysbiosis may increase intestinal permeability, lipopolysaccharide translocation, systemic inflammation, and microglial activation. However, evidence remains heterogeneous and largely observational or experimental. Conclusions: The MD may promote neuroprotection through interconnected diet–microbiome–immune pathways. Longitudinal and intervention studies integrating microbiome, metabolomic, inflammatory, neuroimaging, and cognitive measures are needed to establish causality and advance precision nutrition strategies to prevent neurodegenerative disease.
- Open Access
- 15 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3802
Wearable Nocturnal Autonomic and Sleep Biomarkers for Predicting Next-Day Headache and Identifying Nociplastic Pain in Patients with Migraine
Background/Objectives: The aim of this pilot study was to evaluate the feasibility of developing individualized machine learning models using nocturnal wearable-derived autonomic nervous system (ANS) and sleep metrics to predict next-day headache risk in patients with migraine. We also examined the associations between nocturnal ANS and sleep measures and patient-reported outcome measures (PROMs) related to nociplastic pain, migraine burden, and non-restorative sleep (NRS). Methods: Adults with migraine wore the wrist-worn Empatica EmbracePlus® wearable during sleep and completed daily headache diaries for approximately 4 weeks (N = 10). Participants also completed daily headache diaries and PROMs assessing nociplastic pain, migraine burden, and non-restorative sleep. Personalized machine learning (ML) models were developed to predict next-day headache using nocturnal ANS activity (e.g., pulse rate variability (PRV), electrodermal activity (EDA), respiratory rate (RR)) and sleep metrics (e.g., interruptions, duration, awakenings). Model performance was evaluated using area under the receiver operating characteristic and precision–recall curves (AUROC, AUPRC), sensitivity, specificity, accuracy, and precision. Spearman correlations assessed the relationship between wearable-derived metrics and patient-reported outcome measurements of sleep quality (PROMIS-Fatigue, PROMIS-Sleep Disturbance) and a surrogate marker of nociplastic pain (Fibromyalgia (FM) Score). Results: 9 out of 10 participants wore the EmbracePlus device for at least the target duration of four weeks. For the next-day headache prediction, model performance varied between individuals; area under the ROC curve (AUROC) ranged from 28.2% to 81.2%. Nocturnal measures of EDA were strongly correlated with the FM score (Spearman’s rho = 0.72–0.75, p < 0.05). Conclusions: Phasic EDA may warrant further investigation as a potential physiological indicator related to nociplastic pain mechanisms and next-day headache. However, these findings are preliminary, and larger multicenter trials are needed to confirm results of this pilot study.
- 15 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3802
Open AccessWearable Nocturnal Autonomic and Sleep Biomarkers for Predicting Next-Day Headache and Identifying Nociplastic Pain in Patients with Migraine
Background/Objectives: The aim of this pilot study was to evaluate the feasibility of developing individualized machine learning models using nocturnal wearable-derived autonomic nervous system (ANS) and sleep metrics to predict next-day headache risk in patients with migraine. We also examined the associations between nocturnal ANS and sleep measures and patient-reported outcome measures (PROMs) related to nociplastic pain, migraine burden, and non-restorative sleep (NRS). Methods: Adults with migraine wore the wrist-worn Empatica EmbracePlus® wearable during sleep and completed daily headache diaries for approximately 4 weeks (N = 10). Participants also completed daily headache diaries and PROMs assessing nociplastic pain, migraine burden, and non-restorative sleep. Personalized machine learning (ML) models were developed to predict next-day headache using nocturnal ANS activity (e.g., pulse rate variability (PRV), electrodermal activity (EDA), respiratory rate (RR)) and sleep metrics (e.g., interruptions, duration, awakenings). Model performance was evaluated using area under the receiver operating characteristic and precision–recall curves (AUROC, AUPRC), sensitivity, specificity, accuracy, and precision. Spearman correlations assessed the relationship between wearable-derived metrics and patient-reported outcome measurements of sleep quality (PROMIS-Fatigue, PROMIS-Sleep Disturbance) and a surrogate marker of nociplastic pain (Fibromyalgia (FM) Score). Results: 9 out of 10 participants wore the EmbracePlus device for at least the target duration of four weeks. For the next-day headache prediction, model performance varied between individuals; area under the ROC curve (AUROC) ranged from 28.2% to 81.2%. Nocturnal measures of EDA were strongly correlated with the FM score (Spearman’s rho = 0.72–0.75, p < 0.05). Conclusions: Phasic EDA may warrant further investigation as a potential physiological indicator related to nociplastic pain mechanisms and next-day headache. However, these findings are preliminary, and larger multicenter trials are needed to confirm results of this pilot study.
- Open Access
Distinct Hippocampal Cellular Pathologies Influence Cognition Across Diagnostic Categories and Distinguish Schizophrenia from Affective Psychosis
Cognitive deficits are core features of psychosis and strong predictors of functional outcome, but are largely refractory to pharmacological treatments. It remains unresolved whether these deficits share cellular mechanisms across the psychosis spectrum (as in transdiagnostic models) or differ across DSM-5 diagnostic boundaries, particularly those separating schizophrenia from affective psychoses. We tested this by examining associations between MATRICS Cognitive Battery scores and whole-hippocampal proton magnetic resonance spectroscopic imaging ( 1 H-MRSI) neurometabolite biomarkers of cellular pathologies in 33 participants with psychosis (20 schizophrenia, 13 affective psychosis), 22 with non-psychotic affective disorders, and 25 healthy controls. Metabolite biomarkers included N-acetylaspartate (NAA) for neuronal integrity; myo-inositol (mI) for glia; choline (Cho) for membrane/myelin turnover; and glutamate+glutamine (Glx) for glutamatergic neurotransmission. Metabolite concentrations did not differ between groups but showed group-specific associations with cognition. In healthy controls, lower NAA was associated with poorer overall cognition, working memory, and reasoning (r s =.41, .42, and .43, respectively; p’s<.05). Among non-psychotic affective cases, lower mI and higher Cho were associated with worse verbal learning (r s =.50 and −.45, respectively; p’s<.05). In psychosis, lower Cho predicted poorer visual learning (r s =.51; p=.002). The clearest between-group divergence involved social cognition, the cognitive domain most predictive of functioning in psychosis: worse performance was associated with lower Glx in schizophrenia (r s =.67; p=.033) but higher Cho and NAA in affective psychosis (r s =−.58 and −.58, respectively; p’s<.05). Each metabolite-social cognition association was opposite in direction and differed significantly between these groups (p’s<.05), contrary to what transdiagnostic models would predict. These findings suggest distinct hippocampal cellular substrates of social cognitive impairments in schizophrenia and affective psychosis, supporting diagnosis-specific treatment targets and warranting replication in larger samples.
Open AccessDistinct Hippocampal Cellular Pathologies Influence Cognition Across Diagnostic Categories and Distinguish Schizophrenia from Affective Psychosis
Cognitive deficits are core features of psychosis and strong predictors of functional outcome, but are largely refractory to pharmacological treatments. It remains unresolved whether these deficits share cellular mechanisms across the psychosis spectrum (as in transdiagnostic models) or differ across DSM-5 diagnostic boundaries, particularly those separating schizophrenia from affective psychoses. We tested this by examining associations between MATRICS Cognitive Battery scores and whole-hippocampal proton magnetic resonance spectroscopic imaging ( 1 H-MRSI) neurometabolite biomarkers of cellular pathologies in 33 participants with psychosis (20 schizophrenia, 13 affective psychosis), 22 with non-psychotic affective disorders, and 25 healthy controls. Metabolite biomarkers included N-acetylaspartate (NAA) for neuronal integrity; myo-inositol (mI) for glia; choline (Cho) for membrane/myelin turnover; and glutamate+glutamine (Glx) for glutamatergic neurotransmission. Metabolite concentrations did not differ between groups but showed group-specific associations with cognition. In healthy controls, lower NAA was associated with poorer overall cognition, working memory, and reasoning (r s =.41, .42, and .43, respectively; p’s<.05). Among non-psychotic affective cases, lower mI and higher Cho were associated with worse verbal learning (r s =.50 and −.45, respectively; p’s<.05). In psychosis, lower Cho predicted poorer visual learning (r s =.51; p=.002). The clearest between-group divergence involved social cognition, the cognitive domain most predictive of functioning in psychosis: worse performance was associated with lower Glx in schizophrenia (r s =.67; p=.033) but higher Cho and NAA in affective psychosis (r s =−.58 and −.58, respectively; p’s<.05). Each metabolite-social cognition association was opposite in direction and differed significantly between these groups (p’s<.05), contrary to what transdiagnostic models would predict. These findings suggest distinct hippocampal cellular substrates of social cognitive impairments in schizophrenia and affective psychosis, supporting diagnosis-specific treatment targets and warranting replication in larger samples.
- Open Access
Do Symptom Domains Have Similar Cellular Underpinnings Across Psychiatric Diagnoses: Evidence from 3D Hippocampal MR Spectroscopy
Introduction: The NIMH Research Domain Criteria (RDoC) posits similar cellular pathologies for particular symptom domains across diagnostic categories. Conversely, knowledge that these differ could advance treatment discovery, especially for affective and non-affective psychoses, as studies usually intermix them. Methods: We tested this by comparing metabolite biomarker concentrations for cellular pathologies from whole hippocampal proton magnetic spectroscopic imaging ( 1 H MRSI) with symptoms from the original and five factor PANSS, and the Hamilton Depression and Young Mania Scales. Participants were 26 healthy controls; 22 non-psychotic affective cases (NP-aff); and 33 with psychosis (including 20 schizophrenia (Scz) and 13 affective psychosis (aff-P) cases). Results: PANSS activation factor was related to reductions in all cellular component biomarkers in Scz, including glia, membrane turnover, neural integrity, glutaminergic neurotransmission, and energy metabolism (p’s<.05), but only to energy metabolism in NP-aff (p=.03). Biomarkers for mood symptoms also varied across categories, suggesting gliosis for mania and depression in HC (p’s≤.025), but increased membrane turnover for mania in aff-P (p=.015), and decreased neural integrity and energy metabolism for depression in Scz (p’s<.05). In contrast, negative symptoms and autistic preoccupation were related to reduced glia in both NP-aff and aff-P (p’s<.05). Autistic preoccupation in Scz was related to both reduced glia and membrane turnover (p’s<.05). Only Scz showed a significant finding for positive symptoms, specifically reduced membrane turnover (p=.018). Discussion: These results suggest both distinct and similar cellular pathologies for symptoms across diagnoses, including affective and non-affective psychoses. The differences support categorizing disorders and stratifying different psychoses in research rather than transdiagnostic approaches.
Open AccessDo Symptom Domains Have Similar Cellular Underpinnings Across Psychiatric Diagnoses: Evidence from 3D Hippocampal MR Spectroscopy
Introduction: The NIMH Research Domain Criteria (RDoC) posits similar cellular pathologies for particular symptom domains across diagnostic categories. Conversely, knowledge that these differ could advance treatment discovery, especially for affective and non-affective psychoses, as studies usually intermix them. Methods: We tested this by comparing metabolite biomarker concentrations for cellular pathologies from whole hippocampal proton magnetic spectroscopic imaging ( 1 H MRSI) with symptoms from the original and five factor PANSS, and the Hamilton Depression and Young Mania Scales. Participants were 26 healthy controls; 22 non-psychotic affective cases (NP-aff); and 33 with psychosis (including 20 schizophrenia (Scz) and 13 affective psychosis (aff-P) cases). Results: PANSS activation factor was related to reductions in all cellular component biomarkers in Scz, including glia, membrane turnover, neural integrity, glutaminergic neurotransmission, and energy metabolism (p’s<.05), but only to energy metabolism in NP-aff (p=.03). Biomarkers for mood symptoms also varied across categories, suggesting gliosis for mania and depression in HC (p’s≤.025), but increased membrane turnover for mania in aff-P (p=.015), and decreased neural integrity and energy metabolism for depression in Scz (p’s<.05). In contrast, negative symptoms and autistic preoccupation were related to reduced glia in both NP-aff and aff-P (p’s<.05). Autistic preoccupation in Scz was related to both reduced glia and membrane turnover (p’s<.05). Only Scz showed a significant finding for positive symptoms, specifically reduced membrane turnover (p=.018). Discussion: These results suggest both distinct and similar cellular pathologies for symptoms across diagnoses, including affective and non-affective psychoses. The differences support categorizing disorders and stratifying different psychoses in research rather than transdiagnostic approaches.
- 9 December 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (5) , 1005-1011
When do platform trials in chronic pain make sense?
Clinical trials to develop new, non-addictive, pain medications are costly and labor intensive and might benefit from consolidation within platform trials to allow rapid testing of new agents. We describe our experience with the first National Institutes of Health (NIH)-sponsored attempt at a platform trial for a chronic pain condition (the Early Phase Pain Investigation Clinical Network Platform Protocol (EPPIC-Net-PP) for painful diabetic peripheral neuropathy) and contextualize the EPPIC-Net-PP within platform trials more broadly. A search of clinicaltrials.gov revealed 350 platform trials, the majority of which were cancer-related or targeting an acute illness usually in the inpatient setting (e.g., COVID-19). The remainder (other than EPPIC-Net-PP) fell into one or more categories: 1) industry-sponsored, 2) rare serious diseases, 3) pragmatic trials in common chronic diseases. Among the industry-sponsored studies, Eli Lilly’s Chronic Pain Master Protocol (CPMP) was the only other pain-focused platform; the CPMP successfully studied four investigational agents in three pain conditions over approximately three years, suggesting that the streamlined infrastructure available in industry is an important benefit. Outside industry, successful platforms were launched from within longstanding, clinical trials experienced, research networks with diverse funding sources. The key finding from the EPPIC-Net experience and literature review is that in a successful platform the efficiency of shared infrastructure will outweigh the cost of increased complexity. Efficiency depends on an adequate flow of treatments and funding, which will be challenging for chronic pain platforms outside of industry. Thus, such platforms should focus especially on minimizing complexity through disciplined streamlining of procedures.
- 9 December 2025
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (5) , 1005-1011
When do platform trials in chronic pain make sense?
Clinical trials to develop new, non-addictive, pain medications are costly and labor intensive and might benefit from consolidation within platform trials to allow rapid testing of new agents. We describe our experience with the first National Institutes of Health (NIH)-sponsored attempt at a platform trial for a chronic pain condition (the Early Phase Pain Investigation Clinical Network Platform Protocol (EPPIC-Net-PP) for painful diabetic peripheral neuropathy) and contextualize the EPPIC-Net-PP within platform trials more broadly. A search of clinicaltrials.gov revealed 350 platform trials, the majority of which were cancer-related or targeting an acute illness usually in the inpatient setting (e.g., COVID-19). The remainder (other than EPPIC-Net-PP) fell into one or more categories: 1) industry-sponsored, 2) rare serious diseases, 3) pragmatic trials in common chronic diseases. Among the industry-sponsored studies, Eli Lilly’s Chronic Pain Master Protocol (CPMP) was the only other pain-focused platform; the CPMP successfully studied four investigational agents in three pain conditions over approximately three years, suggesting that the streamlined infrastructure available in industry is an important benefit. Outside industry, successful platforms were launched from within longstanding, clinical trials experienced, research networks with diverse funding sources. The key finding from the EPPIC-Net experience and literature review is that in a successful platform the efficiency of shared infrastructure will outweigh the cost of increased complexity. Efficiency depends on an adequate flow of treatments and funding, which will be challenging for chronic pain platforms outside of industry. Thus, such platforms should focus especially on minimizing complexity through disciplined streamlining of procedures.
- 13 May 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (2) , 338-345
Gastrointestinal Dysmotility, Autonomic Function, and Small Intestinal Bacterial Overgrowth Among People With Well-Controlled HIV
Background: Gastrointestinal dysfunction, including microbiome changes and increased bacterial translocation across a compromised gastrointestinal barrier, plays a role in the chronic systemic inflammation experienced by people with HIV (PWH). It is unknown whether autonomic neuropathy (AN) may contribute to these mechanisms by altering gastrointestinal motility. Methods: This is a cross-sectional study of 100 PWH and 89 controls. All participants underwent assessment of gastrointestinal transit times using a wireless motility capsule. All PWH and a subset of controls also underwent a standardized battery of autonomic function tests summarized as the Modified Composite Autonomic Severity Score (MCASS) and its adrenergic, cardiovagal, and sudomotor subscores, breath testing for small intestinal bacterial overgrowth (SIBO), and the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI-SYM) and Composite Autonomic Symptom Score 31 (COMPASS-31) questionnaires. Results: Compared to controls, PWH displayed shorter gastric emptying times (GET) and longer small bowel and colonic transit times (SBTT, CTT). Among PWH, GET was associated with PAGI-SYM score. The MCASS and its sudomotor subscore (reflecting peripheral sympathetic function) were associated with SBTT but not GET or CTT. PWH with prolonged SBTT (>6 hours) were more likely to have SIBO. Conclusions: Gastrointestinal motility is altered in PWH. This study provides preliminary evidence that changes in autonomic function may influence SBTT in PWH and that prolonged SBTT may contribute to the development of SIBO. Future studies are needed to more fully elucidate the pathophysiologic links between HIV-associated AN, altered gastrointestinal motility, the gastrointestinal microbiome, chronic inflammation, and resulting morbidity and mortality among PWH.
- 13 May 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 232 (2) , 338-345
Gastrointestinal Dysmotility, Autonomic Function, and Small Intestinal Bacterial Overgrowth Among People With Well-Controlled HIV
Background: Gastrointestinal dysfunction, including microbiome changes and increased bacterial translocation across a compromised gastrointestinal barrier, plays a role in the chronic systemic inflammation experienced by people with HIV (PWH). It is unknown whether autonomic neuropathy (AN) may contribute to these mechanisms by altering gastrointestinal motility. Methods: This is a cross-sectional study of 100 PWH and 89 controls. All participants underwent assessment of gastrointestinal transit times using a wireless motility capsule. All PWH and a subset of controls also underwent a standardized battery of autonomic function tests summarized as the Modified Composite Autonomic Severity Score (MCASS) and its adrenergic, cardiovagal, and sudomotor subscores, breath testing for small intestinal bacterial overgrowth (SIBO), and the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI-SYM) and Composite Autonomic Symptom Score 31 (COMPASS-31) questionnaires. Results: Compared to controls, PWH displayed shorter gastric emptying times (GET) and longer small bowel and colonic transit times (SBTT, CTT). Among PWH, GET was associated with PAGI-SYM score. The MCASS and its sudomotor subscore (reflecting peripheral sympathetic function) were associated with SBTT but not GET or CTT. PWH with prolonged SBTT (>6 hours) were more likely to have SIBO. Conclusions: Gastrointestinal motility is altered in PWH. This study provides preliminary evidence that changes in autonomic function may influence SBTT in PWH and that prolonged SBTT may contribute to the development of SIBO. Future studies are needed to more fully elucidate the pathophysiologic links between HIV-associated AN, altered gastrointestinal motility, the gastrointestinal microbiome, chronic inflammation, and resulting morbidity and mortality among PWH.
- 7 April 2025
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 20 (4) , 416-421
Management of pain and other palliative needs in older people with HIV
Purpose of review: Human immunodeficiency virus (HIV) was historically considered a terminal illness. However, medical advancements, including antiretroviral therapy (ART), have extended the lifespan of people with HIV (PWH), emphasizing the importance of maximizing quality of life (QoL) in this aging population. These populations face unique health challenges due to various structural and environmental barriers, and comorbidities. This review aims to consolidate recent data on pain management and other palliative needs in older people with HIV (OPWH). Recent findings: Recent research developments focus on providing relief by incorporation of geriatric and palliative care (PC) principles, use of long-acting injectable-antiretroviral therapies (LAI-ARTs), cannabinoids, exercise and self-management interventions, and tailored cognitive-behavioral therapy (CBT) for older people with HIV (OPWH; ≥50 years). The potential of these novel interventions can fulfil the needs of this underserved demographic suffering from a niche subset of physical and psychosocial issues. Yet, there remains variability in access to these services, with disparities often linked to healthcare infrastructure and socioeconomic factors. Summary: Interventions for an aging population of PWH should take a person-centered approach, balancing different priorities and exploring multiple avenues for symptom relief.
- 7 April 2025
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 20 (4) , 416-421
Management of pain and other palliative needs in older people with HIV
Purpose of review: Human immunodeficiency virus (HIV) was historically considered a terminal illness. However, medical advancements, including antiretroviral therapy (ART), have extended the lifespan of people with HIV (PWH), emphasizing the importance of maximizing quality of life (QoL) in this aging population. These populations face unique health challenges due to various structural and environmental barriers, and comorbidities. This review aims to consolidate recent data on pain management and other palliative needs in older people with HIV (OPWH). Recent findings: Recent research developments focus on providing relief by incorporation of geriatric and palliative care (PC) principles, use of long-acting injectable-antiretroviral therapies (LAI-ARTs), cannabinoids, exercise and self-management interventions, and tailored cognitive-behavioral therapy (CBT) for older people with HIV (OPWH; ≥50 years). The potential of these novel interventions can fulfil the needs of this underserved demographic suffering from a niche subset of physical and psychosocial issues. Yet, there remains variability in access to these services, with disparities often linked to healthcare infrastructure and socioeconomic factors. Summary: Interventions for an aging population of PWH should take a person-centered approach, balancing different priorities and exploring multiple avenues for symptom relief.
- 11 October 2024
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 45 (01) , 063-074
Infectious Neuropathies
This review explores diverse infectious etiologies of peripheral nervous system (PNS) dysfunction, spanning sensory and motor neurons, nerves, and associated structures. Progress in viral and bacterial infections reveals multifaceted mechanisms underlying neuropathies, including viral neurotoxicity and immune-mediated responses. Latest diagnostic advances facilitate early PNS complication detection, with ongoing research offering promising treatment avenues. Emerging pathogens like severe acute respiratory syndrome coronavirus 2, Zika virus, and EV-D68 highlight the evolving infectious neuropathy paradigm. Recognizing characteristic patterns and integrating clinical factors are pivotal for precise diagnosis and tailored intervention. Challenges persist in assessment and management due to varied pathogenic mechanisms. Advancements in understanding pathogenesis have improved targeted therapies, yet gaps remain in effective treatments. Ongoing research is crucial for optimizing approaches and improving patient outcomes.
- 11 October 2024
- Published by Georg Thieme Verlag KG in Seminars in Neurology
- Vol. 45 (01) , 063-074
Infectious Neuropathies
This review explores diverse infectious etiologies of peripheral nervous system (PNS) dysfunction, spanning sensory and motor neurons, nerves, and associated structures. Progress in viral and bacterial infections reveals multifaceted mechanisms underlying neuropathies, including viral neurotoxicity and immune-mediated responses. Latest diagnostic advances facilitate early PNS complication detection, with ongoing research offering promising treatment avenues. Emerging pathogens like severe acute respiratory syndrome coronavirus 2, Zika virus, and EV-D68 highlight the evolving infectious neuropathy paradigm. Recognizing characteristic patterns and integrating clinical factors are pivotal for precise diagnosis and tailored intervention. Challenges persist in assessment and management due to varied pathogenic mechanisms. Advancements in understanding pathogenesis have improved targeted therapies, yet gaps remain in effective treatments. Ongoing research is crucial for optimizing approaches and improving patient outcomes.
- Open Access
Gastrointestinal Dysmotility, Autonomic Function and Small Intestinal Bacterial Overgrowth Among People with Well-Controlled HIV
Introduction Gastrointestinal dysfunction, including microbiome changes and increased translocation across a compromised gastrointestinal barrier plays a role in the chronic inflammation experienced by people with HIV (PWH). It is unknown whether autonomic neuropathy (AN) may contribute to these mechanisms by altering gastrointestinal motility. Methods This is a cross-sectional study of 100 PWH and 89 controls. All participants underwent assessment of gastrointestinal transit times using a wireless motility capsule (WMC). All PWH and a subset of controls also underwent: a standardized battery of autonomic function tests summarized as the Modified Composite Autonomic Severity Score (MCASS) and its adrenergic, cardiovagal and sudomotor sub-scores, breath testing for small intestinal bacterial overgrowth (SIBO), and the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI-SYM) and Composite Autonomic Symptom Score 31 (COMPASS-31) questionnaires. Results PWH displayed shorter gastric emptying times (GET) and longer small bowel and colonic transit times (SBTT, CTT) compared to controls. Among PWH, GET was associated with PAGI-SYM score. The MCASS and its sudomotor sub-score (reflecting peripheral sympathetic function) were associated with SBTT but not GET or CTT. PWH with prolonged SBTT (>6h) were more likely to have SIBO. Conclusion Gastrointestinal motility is altered in PWH. This study provides preliminary evidence that changes in autonomic function may influence SBTT in PWH and that prolonged SBTT may contribute to the development of SIBO. Future studies are needed to more fully elucidate the pathophysiologic links between HIV-associated AN, altered gastrointestinal motility, the gastrointestinal microbiome, chronic inflammation, and resulting morbidity and mortality among PWH.
Open AccessGastrointestinal Dysmotility, Autonomic Function and Small Intestinal Bacterial Overgrowth Among People with Well-Controlled HIV
Introduction Gastrointestinal dysfunction, including microbiome changes and increased translocation across a compromised gastrointestinal barrier plays a role in the chronic inflammation experienced by people with HIV (PWH). It is unknown whether autonomic neuropathy (AN) may contribute to these mechanisms by altering gastrointestinal motility. Methods This is a cross-sectional study of 100 PWH and 89 controls. All participants underwent assessment of gastrointestinal transit times using a wireless motility capsule (WMC). All PWH and a subset of controls also underwent: a standardized battery of autonomic function tests summarized as the Modified Composite Autonomic Severity Score (MCASS) and its adrenergic, cardiovagal and sudomotor sub-scores, breath testing for small intestinal bacterial overgrowth (SIBO), and the Patient Assessment of Upper Gastrointestinal Disorders Symptoms (PAGI-SYM) and Composite Autonomic Symptom Score 31 (COMPASS-31) questionnaires. Results PWH displayed shorter gastric emptying times (GET) and longer small bowel and colonic transit times (SBTT, CTT) compared to controls. Among PWH, GET was associated with PAGI-SYM score. The MCASS and its sudomotor sub-score (reflecting peripheral sympathetic function) were associated with SBTT but not GET or CTT. PWH with prolonged SBTT (>6h) were more likely to have SIBO. Conclusion Gastrointestinal motility is altered in PWH. This study provides preliminary evidence that changes in autonomic function may influence SBTT in PWH and that prolonged SBTT may contribute to the development of SIBO. Future studies are needed to more fully elucidate the pathophysiologic links between HIV-associated AN, altered gastrointestinal motility, the gastrointestinal microbiome, chronic inflammation, and resulting morbidity and mortality among PWH.
- Open Access
- 25 September 2024
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 36 (1) , 69-80
Perceived Stress and Health Outcomes Among Latinx and Non-Latinx White Adult People With HIV in East Harlem, New York: A Cross-Sectional Study
Stress and HIV disproportionately affect Latinx adults in the United States, contributing to numerous health inequities. Among people living with HIV (PLWH), increased stress is associated with decreased medication adherence, effectiveness, and higher rates of immunosuppression and comorbidities. Our study (N = 126) examined the relationship between perceived stress and HIV-related health among Latinx (n = 83) and non-Latinx White (n = 43) PLWH. Latinx PLWH reported better HIV-related health outcomes than non-Latinx White PLWH, despite higher viral load (all p's < .05). An interaction effect showed that higher perceived distress was associated with worse health outcomes and lower CD4+ T cell count only in Latinx PLWH (p's < .05). Our findings highlight the consequences of stress on HIV-related health. Notably, higher stress may be especially detrimental among Latinx PLWH, underscoring the need for more culturally tailored interventions in HIV-related care. Future research should include additional sociocultural factors and longitudinal assessment in a larger sample.
- 25 September 2024
- Published by Wolters Kluwer Health in Journal of the Association of Nurses in AIDS Care
- Vol. 36 (1) , 69-80
Open AccessPerceived Stress and Health Outcomes Among Latinx and Non-Latinx White Adult People With HIV in East Harlem, New York: A Cross-Sectional Study
Stress and HIV disproportionately affect Latinx adults in the United States, contributing to numerous health inequities. Among people living with HIV (PLWH), increased stress is associated with decreased medication adherence, effectiveness, and higher rates of immunosuppression and comorbidities. Our study (N = 126) examined the relationship between perceived stress and HIV-related health among Latinx (n = 83) and non-Latinx White (n = 43) PLWH. Latinx PLWH reported better HIV-related health outcomes than non-Latinx White PLWH, despite higher viral load (all p's < .05). An interaction effect showed that higher perceived distress was associated with worse health outcomes and lower CD4+ T cell count only in Latinx PLWH (p's < .05). Our findings highlight the consequences of stress on HIV-related health. Notably, higher stress may be especially detrimental among Latinx PLWH, underscoring the need for more culturally tailored interventions in HIV-related care. Future research should include additional sociocultural factors and longitudinal assessment in a larger sample.